Fri, Sep 19, 2014, 6:25 AM EDT - U.S. Markets open in 3 hrs 5 mins


% | $
Quotes you view appear here for quick access.

Sarepta Therapeutics, Inc. Message Board

  • zwerp2000 zwerp2000 Jul 1, 2013 12:21 PM Flag

    Comments by festivus from this past weekends meeting ; part 1

    Here is a writeup of some of what was discussed at the PPMDconnect conference. I tried to be as accurate as possible, but if anybody else watched the webcast, let me know if I missed anything, or need to correct anything.

    Disclosure: I am long SRPT

    There is a summary at the end with my comments.

    Overall, the respective companies have already previously discussed most of the things mentioned.

    Dr. Bob Temple
    - Orphan diseases can have pivotal, small, single arm trials
    - If there is a clear signal of clinical effect then it’s not really the size of the trial that matters
    - Often historical controls are used, but the current exon skipping drug trials all do have placebo controls, at least initially.
    - Specifically, surrogate marker of Becker-like dystrophin biopsy is a question, answer has been decided, but cannot reveal, and was trying to sound as impartial as possible.
    - States that it is produced in the muscle so whether it gets to correct location is not an issue.
    - Suggests that more of it is probably better than less, and it’s still a question of whether this type of dystrophin is clinically relevant → this is the question for whether it’s a good surrogate.
    - States that it is good to be able to correlate surrogate with a clinical endpoint to prove validity.
    - Stabilization over a year and a half, or stabilization after an initial decline can potentially be persuasive, if this is not expected based on natural history → seems like both are reference to Sarepta trial → I will discuss natural history at the end.

    - Didn’t catch the beginning of the talk
    - Want to incorporate immunofluorescence (IF) intensity into dystrophin IF measurements (as opposed to just % positive dystrophin fibers)
    - Dystrophin IF from Becker patients didn’t directly correlate directly with disease progression.
    - Looking at other measures, such as miRNA profile of dystrophic tissue & MRI for surrogate markers.

22.53-0.41(-1.79%)Sep 18 4:15 PMEDT

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.